<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941003-0-00068</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Content of a notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  In the notice, the applicant shall cite section 505(b)(3)(B) of the act and shall include, but not be limited to, the following information:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (1) A statement that a 505(b)(2) application submitted by the applicant has been filed by FDA.  <!-- PJG 0012 frnewline --> (2) The application number.  <!-- PJG 0012 frnewline --> (3) The established name, if any, as defined in section 502(e)(3) of the act, of the proposed drug product.  <!-- PJG 0012 frnewline --> (4) The active ingredient, strength, and dosage form of the proposed drug product.  <!-- PJG 0012 frnewline --> (5) The patent number and expiration date, as submitted to the agency or as known to the applicant, of each patent alleged to be invalid, unenforceable, or not infringed.  <!-- PJG 0012 frnewline --> (6) A detailed statement of the factual and legal basis of the applicant's opinion that the patent is not valid, unenforceable, or will not be infringed. The applicant shall include in the detailed statement:  <!-- PJG 0012 frnewline --> (i) For each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed.  <!-- PJG 0012 frnewline --> (ii) For each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds supporting the allegation.  <!-- PJG 0012 frnewline --> (7) If the applicant does not reside or have a place of business in the United States, the name and address of an agent in the United States authorized to accept service of process for the applicant.  <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amendment to an application. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  If an application is amended to include the certification described in &sect;314.50(i), the applicant shall send the notice required by paragraph (a) of this section at the same time that the amendment to the application is submitted to FDA.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (e)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Documentation of receipt of notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  The applicant shall amend its application to document receipt of the notice required under paragraph (a) of this section by each person provided the notice. The applicant shall include a copy of the return receipt or other similar evidence of the date the notification was received. FDA will accept as adequate documentation of the date of receipt a return receipt or a letter acknowledging receipt by the person provided the notice. An applicant may rely on another form of documentation only if FDA has agreed to such documentation in advance. A copy of the notice itself need not be submitted to the agency.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (f)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Approval. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  If the requirements of this section are met, the agency will presume the notice to be complete and sufficient, and it will count the day following the date of receipt of the notice by the patent owner or its representative and by the approved application holder as the first day of the 45-day period provided for in section 505(c)(3)(C) of the act. FDA may, if the applicant amends its application with a written statement that a later date should be used, count from such later date.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;314.53  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Submission of patent information.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Who must submit patent information. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  This section applies to any applicant who submits to FDA a new drug application or an amendment to it under section 505(b) of the act and &sect;314.50 or a supplement to an approved application under &sect;314.70, except as provided in paragraph (d)(2) of this section.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Patents for which information must be submitted. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  An applicant described in paragraph (a) of this section shall submit information on each patent that claims the drug or a method of using the drug that is the subject of the new drug application or amendment or supplement to it and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product. For purposes of this part, such patents consist of drug substance (ingredient) patents, drug product (formulation and composition) patents, and method of use patents. Process patents are not covered by this section and information on process patents may not be submitted to FDA. For patents that claim a drug substance or drug product, the applicant shall submit information only on those patents that claim a drug product that is the subject of a pending or approved application, or that claim a drug substance that is a component of such a product. For patents that claim a method of use, the applicant shall submit information only on those patents that claim indications or other conditions of use of a pending or approved application.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            